Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin and CV events in PAD patients

This article was originally published in The Tan Sheet

Executive Summary

A meta-analysis concludes aspirin treatment provides a significant reduction in nonfatal stroke in patients with peripheral artery disease, but a statistically nonsignificant decrease in cardiovascular events compared to placebo. According to a study in the Journal of the American Medical Association May 13, "additional randomized controlled trials of aspirin therapy are needed to establish the net benefit and bleeding risks in PAD." The researchers, led by Jeffrey Berger of the University of Pennsylvania, synthesized data from 5,269 participants but say the meta-analysis is limited because many of the trials studied were small and of short duration
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS102908

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel